1831128-32-5
1831128-32-5
Chemical Structure
Lacnotuzumab
Synonym(s): MCS110
- CAS No.: 1831128-32-5
- Formula:N/A
- Molecular Weight:(144.8 kDa)
IUPAC Name: (2Z,4E)-5-((R)-1-hydroxy-2-(hydroxymethyl-d2)-6,6-dimethyl-4-oxocyclohex-2-en-1-yl-3,5,5-d3)-3-methylpenta-2,4-dienoic acid
SMILES: [Lacnotuzumab]
Biological Activity: Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lacnotuzumab | 99.9% | Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kuemmel S, et, al. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Jan 1;28(1):106-115. [Content Brief]
- [2]. Pognan F, et, al. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442. [Content Brief]
